Piperidine GPCR agonists
A technology of CH2 and compounds, applied in the field of G protein-coupled receptor agonists, can solve problems such as dyslipidemia in a high proportion of patients
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0211] Example 1: 4-{3-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]propoxy}-2-methyl -N-(tetrahydropyran-4-yl)benzamide
[0212]
[0213] HOBt·H 2 O (46.0 mg, 338 micromoles) and EDCI (65.0 mg, 338 micromoles) were added to stirred 4-{3-[1-(3-isopropyl-[1,2,4] oxadiazol-5-yl)piperidin-4-yl]propoxy}-2-methylbenzoic acid (preparation 4, 100 mg, 260 micromoles) in solution. After 15 minutes, tetrahydropyran-4-ylamine (53.0 mg, 520 micromole) was added and the resulting mixture was stirred at ambient temperature for 16 hours. The THF was removed in vacuo and the residue was partitioned with EtOAc and 2M NaOH. The organic phase was separated and washed with 2M NaOH, 1M HCl and brine, then dried (MgSO 4 ). Filtration and solvent evaporation provided the title compound: RT = 3.69 min; m / z (ES + )=471.28[M+H] + (Method A).
[0214] Using a method similar to that outlined in Example 1, the amines listed in Table 1 were synthesized by condensing the appropriate acid ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


